B.S. in Life Science, Peking University;

Ph.D. in Neuroscience, University of British Columbia;

Previous Postdoctoral fellow of Neurology and ICE, Johns Hopkins University;

Dr. Fan has been elected as one of the' 30 Global Innovative talents of Chinese entrepreneurs' in 2018;

17 years of research experience in stroke and neurodegenerative disease models and mechanisms. 10 years of experience in pluripotent stem cell culture, iPSC reprogramming and neural differentiation. Since 2017, Dr. Fan has led the Hopstem team and together established the company's intellectual property layout and iPSC cell product R&D platform.

Former SVP of AbPro;

Founder and CEO of Jemincare Therapeutics;

VP of BD of HD Bioscience;

Sr.Director of BD of WuXiAppTec.25 years of research;

BD and management experience in pharmaceutical companies.

Peking University Health Science Center, Master of Medicine;

Rensselaer Polytechnic Institute, USA, Ph.D.;

Albany Medical Center, USA, Postdoc;

University of Washington, USA, Instructor;

Associate professor；

Hangzhou Future Sci & Tech City Overseas High-level Talent. 2018;

As the outstanding figure in Hangzhou’s Academician Station, highlighted in Hangzhou Youth Newspaper. 2019;

Core member of Leading Innovation Team Award by Zhejiang Province. 2020;

Leader of Outstanding Team Award of Huadong Medicine. 2020;

Served as Medical director in Hangzhou Adamerck, Head of Clinical Medicine and Medical Affairs department in Huadong Medicine. In charge of the clinical development of multiple projects from IND to NDA, as well as project leaders for multiple licensed-in projects.

Master of Science in Biotechnology, Johns Hopkins University, USA

Former Director/Board Member, QUALES, LLC, Frederick, MD

Former R&D Scientist I, Analytical Biotechnology/High-Throughput Method Development Group, MEDIMMUNE/ASTRAZENECA, Gaithersburg, MD

Former Vice Chairman of Business Advisory Board, Biomedical Science, ADVANCE MEDIGENE, INC, Gaithersburg, MD

Over 20 years extensive biopharmaceutical experience in the Chemical Manufacturing and Control field. Ms. Wang Demonstrated success leading teams in implementing product quality control strategies to monitor upstream processes and identify critical quality attributes

Mainly responsible for the quality assurance and control. Nominated as the Qualified Person (QP) of the company

Ph.D. in Biophysics, University of Chinese Academy of Sciences;

Previous Research Associate (Postdoc), University of Wisconsin-Madison;

Experienced with iPSC/ESC culture and glia / neural differentiation. Dr. Wang has completed high-content and high-throughput screening of human glial cells and neurons derived from iPSC from Rett Syndrome patients at UWM. He leads the Hopstem R&D team to develop innovative iPSC cell products.

Ph.D. and postdoctoral fellow in Chemistry-Biomaterials, Technical University of Berlin;

More than 10 years of experience in stem cell nanomaterials and cytotoxicity study;

Responsible for clinical product development in Hopstem.

Ph.D. in neuroscience, School of medicine, Zhejiang University;

More than 10 years of training in Neuroscience, Cell Biology, and CRISPR gene editing;

Responsible for QC method development and technical support in Hopstem.

Master’s Degree of Nanjing University of Chinese Medicine;

25 years of experience in pharmaceutical registration, including First-in-Class new drugs, cell therapy products, and experience for China/US IND application;

Worked for Simcere Pharmaceutical, Nanjing King-Friend and MITRO Biotech;

Responsible for domestic/overseas registration in Hopstem.